Douglas Laboratories® Introduces Supercritical Omega-3
Written by TAC Staff   
Sunday, 18 September 2011 20:17

quelldouglaslabsPITTSBURGH, PA – Douglas Laboratories, a leader in innovation in the professional healthcare supplementation market, is proud to introduce its newest, most potent form of omega-3 supplementation: QÜELL Omega-3 Fish Oil. The QÜELL difference lies in its supercritical CO2 extraction method, providing a highly concentrated triglyceride form of omega-3.

Using supercritical CO2 extraction technology, omega-3 fatty acids are extracted without high temperatures, oxygen or chemical solvents, ensuring that the oil is protected from oxidation, microbiological contamination, solvent residue and isomer formation. This is also the preferred extraction method as it is more environmentally responsible and also purifies and concentrates to a higher degree. Additionally, a growing body of scientific evidence supports the triglyceride (or re-esterfied triglyceride) form of the fatty acids as having the greatest absorption (compared to the ethyl ester form), significantly increasing the index of EPA and DHA in the blood. QÜELL Omega-3 Fish Oil is unique in that it is the only fish oil on the market utilizing supercritical CO2 extracted fish oil in a triglyceride form to achieve the highest benefits.

“We are always looking for ways to make tried and true products even better,” says Dr. Andrew Halpner, PhD. “Using precision German engineering and manufacturing, we can offer fish oil products that use this unique supercritical CO2 technology provides a unique extraction method. We can now provide an enhanced omega-3 product with critical purity due to extremely low levels of contaminants; critical bioavailability for better absorption; and critical concentration of EPA and DHA—so patients can reap the benefits of the purest fish oil on the market.“

QÜELL Omega-3 Fish Oil contains highly concentrated amounts (75%) of essential fatty acids DHA and EPA—providing more DHA and EPA per capsule than other leading brands.  Additionally, Douglas Laboratories’ QÜELL Fish Oils come in a fish gelatin softgel making it more suitable for patients not wanting to take bovine or porcine gelatin. They provide less odor and taste due to the supercritical CO2 purification process, allowing for a more pleasant experience when consuming fish oil.   

QÜELL Omega-3 Fish Oil comes in 3 versions: High EPA, High DHA, and High EPA + DHA with Vitamin D. It is now available to healthcare practitioners exclusively through Douglas Laboratories. For more information on QÜELL Omega 3 Fish Oil and to view our Supercritical QÜELL video, visit

Subsidiary of Atrium Innovations Inc. [TSX: ATB], Douglas Laboratories, the trusted choice of thousands of healthcare professionals for more than 50 years, is at the forefront of the nutritional health industry, proudly researching, developing and manufacturing superior quality, science-based supplements that help people improve their health. Recognized throughout the industry for its uncompromising operational practices at its state-of-the-art, GMP-compliant manufacturing facilities, Douglas Laboratories continues to provide the added insurance of multiple domestic and international GMP certifications, including ISO-9001 certification and ISO-17025 accreditation for in-house laboratories, as well as NSF International Registration. Douglas Laboratories currently offers more than 600 branded products, introducing new products on a continuous basis. Working with an experienced research staff of PhDs and a prestigious medical advisory board, Douglas Laboratories is committed to bringing innovative, science-based products to the marketplace. Douglas Laboratories distributes worldwide, with its headquarters located in Pittsburgh, Pennsylvania, USA. For additional information, visit             

ChiroTouch To Host Critical Webinar with Dr. Patrick Gentempo and Richard Sapio
Written by TAC Staff   
Tuesday, 13 September 2011 16:34


chirotouchcomputer2San Diego, CA – Sept 8th, 2011 – ChiroTouch™, the nation's leader in chiropractic software, is welcoming Dr. Patrick Gentempo and Richard Sapio as the hosts for "Chiro Finishing School – The 12 Foundational Principles of Business,"  which will air live for one hour on September 15th, 2011 at 10:30 AM (PDT).
“At the center of all business, regardless of industry, are the mechanisms for growth” said Robert Moberg, President of ChiroTouch.  “Creating and sustaining a healthy, thriving chiropractic practice has a direct impact on a doctor's ability to better serve their patients.  I can't think of two experts that are more qualified to address the business of chiropractic, Dr. Patrick Gentempo, Co-Founder and Chairman of Chiropractic Leadership Alliance, Inc. (CLA) & Rick Sapio, lifelong entrepreneur and Co-Founder of Chiro Finishing School.
Dr. Patrick Gentempo, Jr. is co-founder and Chairman of the Chiropractic Leadership Alliance (CLA) which has over 8,000 chiropractic clients on 6 continents. He is an internationally renowned visionary, lecturer, business leader and author. As one of the largest draws in chiropractic today, he is considered to be unmatched in his ability to integrate the philosophy, science, clinical practice and business of chiropractic without contradiction. Over the past 20 years, Dr. Gentempo has mesmerized audiences with his vision of world leadership of health care in a chiropractic model. He has received numerous awards of the highest level within the chiropractic profession. Dr. Gentempo has also provided testimony to the White House Commission on Complimentary and Alternative Medicine and in 2007 was inducted into the Wellness Hall of Fame. He has appeared on many popular television and radio programs.
Richard ("Rick") Sapio, is a lifelong entrepreneur who started his first company, a bicycle repair shop, after the death of his father, when he was 14 years old. Since then, he has founded more than 20 companies. After graduating from Rutgers University, Rick worked in the investment industry, and traded distressed securities. Shortly thereafter, he became the youngest partner at his firm, after leading more than $100 million in transactions in one year, while he was still in his mid-twenties.
Join Dr. Patrick Gentempo and Rick Sapio as they show you:
  • The principles of business that can leverage your time and money toward long-term growth.
  • Why, in this extremely uncertain economic time, that learning how to be a better business person, could be the most important thing you do.
  • How to execute on true business structure and economic systems, rather than emotion.
  • The keys to inserting the following values into your practice:  Simplicity, Probability, and Leverage.
  • How to become a better business person equipped to improve the health of our society and therefore lift the entire Chiropractic profession!
Chiropractic software designed from the ground up to maximize efficiencies for virtually every process, including patient self check-in, scheduling, SOAP notes, billing, interoffice communication and more, ChiroTouch has developed its HIPAA-compliant system to drastically reduce the time it takes to perform tasks that chiropractors are already doing.  That gives chiropractors more time to see more patients—resulting in increased referrals, improved efficiencies, and a direct, measurable impact on practice profitability.
Other recent webinar topics include ‘Market with Corporate Spinal Screenings and Explode with New Patients,’  ‘Building Value in Your Practice and Equity in Your Business,’ and ‘HITECH Stimulus Act Updates.’  The ChiroTouch webinar programs and the attendees have benefited from speakers such as Dr. Bob Hoffman, Dr. Eric Plasker, Dr. Ron Oberstein, Dr. Mark Ott, Dr. Brad Glowaki, Stanley Greenfield, and many more.  This cross-section of the most influential and recognized coaches and speakers has made for a very robust and popular series of webinars.
Join Dr. Gentempo and Rick Sapio by visiting
To see a calendar of upcoming webinars, please visit
About ChiroTouch
ChiroTouch, by Integrated Practice Solutions Inc., is the premier provider of innovative chiropractic software technology solutions for the chiropractic industry. Fusing advanced software systems with superior support services, we partner with chiropractors across the country to help them automate operations, improve patient care, and increase profitability.  Visit
Valproate Products: Drug Safety Communicaton - Risk of Impaired Cognitive Development in Children Exposed In Utero (During Pregnancy)
Written by TAC Staff   
Friday, 01 July 2011 17:05
Including valproate sodium (Depacon), divalproex sodium (Depakote, Depakote CP, and Depakote ER), valproic acid (Depakene and Stavzor), and their generics

medwatchAUDIENCE: OBGYN, Neurology, Psychiatry

ISSUE: FDA notified healthcare professionals that children born to mothers who take the anti-seizure medication valproate sodium or related products (valproic acid and divalproex sodium) during pregnancy have an increased risk of lower cognitive test scores than children exposed to other anti-seizure medications during pregnancy. This conclusion is based on the results of epidemiologic studies that show that children born to mothers who took valproate sodium or related products throughout their pregnancy tend to score lower on cognitive tests (IQ and other tests) than children born to mothers who took other anti-seizure medications during pregnancy. See the Drug Safety Communication for a data summary and additional information.

pregnantBACKGROUND: Valproate products are FDA-approved drugs to treat seizures, and manic or mixed episodes associated with bipolar disorder (manic-depressive disorder), and to prevent migraine headaches. They are also used off-label (for unapproved uses) for other conditions, particularly for other psychiatric conditions.

RECOMMENDATION: Healthcare professionals should inform women of childbearing age of the increased risk for adverse effects on cognitive development with prenatal valproate exposure, and should continue to counsel women of childbearing potential taking valproate about the increased risk of major malformations, including neural tube defects, when valproate is used during pregnancy. In addition, healthcare professionals should weigh the benefits and risks of valproate when prescribing this drug to women of childbearing age, particularly when treating a condition not usually associated with permanent injury or death. Alternative medications that have a lower risk of adverse birth outcomes should be considered. Patients should not stop taking valproate without talking to a healthcare professional.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

  • Complete and submit the report Online:
  • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

Read the MedWatch safety alert, including links to the Drug Safety Communication and FDA Questions and Answers, at:

Chiropractor Tapped by Cornell and Einstein Medical Schools
Written by TAC Staff   
Tuesday, 21 June 2011 13:13

kathydooleynyccSENECA FALLS, NY: New York Chiropractic College’s first Master of Science in Clinical Anatomy (MSCA) fellow, Kathy Dooley, DC, accepted a teaching consultant (adjunct professor) position at Cornell Medical College and Einstein College of Medicine and will be teaching gross anatomy lab to medical students at both colleges.

Dooley intends to further develop her teaching skills at the medical colleges while building a practice in chiropractic and acupuncture. Having earned a DC degree in 2007 and begun her acupuncture studies at the Finger Lakes School of Acupuncture and Oriental Medicine of NYCC - a program she called “fantastic” – she now plans to complete her acupuncture master’s course work in New York City while practicing and teaching. “I am so immensely grateful to the faculty and staff of NYCC. Without amazing mentors like Dr. Rob Walker my life would not have been possible. I am extremely happy, and doors seem to be flying open due to my experience gained at NYCC in the MSCA program,” she said.

Zocor (simvastatin): Label Change - New Restrictions, Contraindications, and Dose Limitations
Written by TAC Staff   
Friday, 10 June 2011 16:48
Simvastatin sold under the brand-name Zocor, as a single-ingredient generic product, and sold in combination with ezetimibe as Vytorin and in combination with niacin as Simcor

medwatchAUDIENCE: Family Practice, Cardiology, Pharmacy

ISSUE: FDA notified healthcare professionals that it is recommending limiting the use of the highest approved dose of the cholesterol-lowering medication simvastatin (80 mg) because of increased risk of muscle damage. Patients taking simvastatin 80 mg daily have an increased risk of myopathy compared to patients taking lower doses of this drug or other drugs in the same class. This risk appears to be higher during the first year of treatment, is often the result of interactions with certain medicines, and is frequently associated with a genetic predisposition toward simvastatin-related myopathy. The most serious form of myopathy, called rhabdomyolysis, can damage the kidneys and lead to kidney failure which can be fatal. FDA is requiring changes to the simvastatin label to add new contraindications (should not be used with certain medications) and dose limitations for using simvastatin with certain medicines.

BACKGROUND: The new changes to the drug labels for simvastatin-containing medicines are based on FDA's review of the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) trial and other data described in the Agency's March 2010 Ongoing safety review of high-dose Zocor (simvastatin) and increased risk of muscle injury. Simvastatin 80 mg should be used only in patients who have been taking this dose for 12 months or more without evidence of muscle injury (myopathy).

RECOMMENDATION: Simvastatin 80 mg should not be started in new patients, including patients already taking lower doses of the drug.  

Healthcare professionals and patients are encouraged to report adverse events, side effects, or product quality problems related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

  • Complete and submit the report Online:
  • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

Read the MedWatch safety alert, including links to the FDA Drug Safety Communication, Press Release, and Consumer Update, at:


Page 10 of 20



Recent Comments



TAC Publications

The American Chiropractor Magazine: Digital Issues | Past Issues | Buyer's Guide


More Information

TAC Editorial: About | Circulation | Contact

Sales: Advertising | Subscriptions | Media Kit